A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature

Overview

After the first stage (52 weeks) of Phase II clinical trial, Pegylated recombinant human growth hormone (PEG-rhGH) injection of appropriate dose in compliance with ISS clinical treatment strategy is used to treat children with ISS (Idiopathic Short Stature). The long-term efficacy and safety of the investigational product are evaluated, which can provide more scientific and reliable medication guidance information for clinical diagnosis and treatment.

Full Title of Study: “A Phase 2 Study Extension Period of Pegylated Somatropin (PEG-somatropin) in the Treatment of Children With Idiopathic Short Stature: An Open, Non-controlled Observational Study.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2030

Interventions

  • Drug: PEG-somatropin
    • After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.

Arms, Groups and Cohorts

  • Experimental: PEG-somatropin
    • After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for the high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.

Clinical Trial Outcome Measures

Primary Measures

  • Change of yearly height velocity (ΔHV)
    • Time Frame: Baseline,the end of 3-year addendum
    • Change of yearly height velocity before and after treatment. Yearly Height Velocity=12×(Height Yx – Height at Baseline)/(Date of Yx – Date of Baseline)(Yx refers to the height value at particular timepoint x)

Secondary Measures

  • Standard deviation score of height at the actual age (ΔHT SDS)
    • Time Frame: Baseline,every 3 months,the end of 3-year addendum
    • Standard deviation score of height at the actual age.
  • Change fo Bone maturation
    • Time Frame: Baseline,every 3 months,the end of 3-year addendum
    • Change fo Bone maturation before and after treatement (bone age/chronological age)
  • Change of IGF-1 SDS (ΔIGF-1 SDS)
    • Time Frame: Baseline,every 3 months,the end of 3-year addendum
    • Change of IGF-1 SDS before and after treatement
  • Changes of standard deviation scores of body mass index (ΔBMI SDS)
    • Time Frame: Baseline,every 3 months,the end of 3-year addendum
    • Changes of standard deviation scores of body mass index
  • The yearly average dose of PEG-rhGH injection
    • Time Frame: Baseline,every 3 months,the end of 3-year addendum
  • Final height (FH)
    • Time Frame: Baseline,every 3 months,the end of 3-year addendum
    • Final height
  • The improvement of FH compared with the baseline predicted adult height (PAH)
    • Time Frame: Baseline,every 3 months,the end of 3-year addendum
  • Improvement of NAH (near adult height)
    • Time Frame: Baseline,every 3 months,the end of 3-year addendum
    • For subjects who reach NAH with treatment but fail to follow-ups before reaching FH, the improvement of NAH in comparison with the baseline PAH (predicted adult height) shall be evaluated
  • the improvement of PAH
    • Time Frame: Baseline,every 3 months,the end of 3-year addendum
    • For subjects who fail to reach NAH with treatment and fail to follow-ups before reaching FH, the improvement of PAH in comparison with the baseline PAH shall be evaluated
  • The changes of the scores evaluated by the Quality of Life Scale
    • Time Frame: Baseline,every 3 months,the end of 3-year addendum
  • The changes of lean body mass (LBM) (optional)
    • Time Frame: Baseline,every 3 months,the end of 3-year addendum
  • The changes of fat mass (torso) (FM) (optional)
    • Time Frame: Baseline,every 3 months,the end of 3-year addendum
  • The changes of the percentage of body fat (optional)
    • Time Frame: Baseline,every 3 months,the end of 3-year addendum
  • The changes of bone mineral density (BMD) (optional)
    • Time Frame: Baseline,every 3 months,the end of 3-year addendum

Participating in This Clinical Trial

Inclusion Criteria

  • All subjects who have completed the first stage (52 weeks) of Phase II clinical trial (including negative controls) with completed follow-up records may be enrolled in the extension period study. – Before the extension period study, the investigator shall fully inform the subjects and their guardians of all the information about the extension period study, including detailed follow-up procedure, treatment plan, laboratory examination items during follow-ups and possible benefits and risks. The extension period study shall only be initiated after the subjects and their guardians are well informed, and agree to cooperate and complete the treatment, follow-ups and examinations during the study, and sign the written informed consent. Exclusion Criteria:

  • Subjects who have taken the following medications within 2 months before entering the extension period study: 1. Aromatase inhibitors (which include but are not limited to Lelrozol and Anastrozole), with continuous medication ≥1 month; 2. Gonadotropin releasing hormone analogues (which include but are not limited to Triptorelin, Leuprorelin and Goserelin),, with continuous medication ≥1 month; 3. Sex steroids (which include but are not limited to any type of estrogen, progestin and androgen) , with continuous medication ≥1 month; 4. Protein anabolic drugs (which include but are not limited to Oxandrolone, Danazol and Strombafort), with continuous medication ≥1 month; 5. Glucocorticoids via oral/intravenous administration for more than 1 month..

Gender Eligibility: All

Minimum Age: 4 Years

Maximum Age: 9 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Changchun GeneScience Pharmaceutical Co., Ltd.
  • Collaborator
    • Tongji Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Xiaoping Luo, Principal Investigator, Department of Pediatrics of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.